



PROSONIX ANNOUNCES PUBLICATION OF JOINT PATENT FOR NOVEL COMBINATION INHALATION THERAPY WITH CHIESI

22nd September 2010

Prosonix (Oxford, UK) is delighted to announce the publication of patent WO/2010/097188 with Chiesi (Italy) where Drs Graham Ruecroft and Dipesh Parikh are named as co-inventors. The application relates to the preparation and formulation of unique UMAX[®] combination particles for use in pharmaceutical formulations for inhalation, wherein each particle comprises of a pharmaceutically acceptable salt of a long acting β_2 agonist and a corticosteroid, selected from a diverse group of such compounds including beclomethasone dipropionate (BDP), budesonide, ciclesonide, mometasone.

The long acting beta agonist (LABA) is very potent and is administered by inhalation at a very low daily therapeutic dose ranging from 1 to 4 micrograms. It is currently under development by Chiesi in the form of a pharmaceutically acceptable salt in combination with a corticosteroid, in ratios of 1:50. Given the extremely low dose of the β_2 agonist required, classical physical blending of the two jet milled active pharmaceutical ingredients results in high variability of the dry powder formulation. Variability is further compounded by high levels of amorphous content in either or both of the constituent drug substances. This variability can lead to a very high risk of underdosing or overdosing presenting an unacceptable risk to patients, and may in turn lead to a non-registerable product.

In a unique solution to this common problem associated with combination inhalation therapy, Prosonix UMAX[®] technology facilitates the production and delivery of unique crystalline particles comprising of a combination of the LABA and corticosteroid in a predetermined and constant ratio across the full volume of the lung. The excellent content uniformity of the UMAX[®] particles also help to achieve 100% co-deposition of the combination of the active drug substances at the target cell of the lungs, and may ultimately deliver superior therapeutic benefit due to enhanced synergistic action.

Commenting on the recent publication, David Hipkiss, CEO, said:

“This new published patent represents a potential paradigm shift in the way combination inhalation therapies are designed and delivered by first intent, and offers tremendous potential advantages in terms of compliance, convenience and biological effect. To have achieved such a level of control and performance with such a potent API combination is yet further validation of Prosonix technology, underpinning its potential as being the key to enabling and developing the next generation of respiratory medicines.”

For more information contact:

David Hipkiss
CEO
Prosonix Ltd
Magdalen Centre
Oxford Science Park
Oxford
OX4 4GA, UK

Tel + 44 (0) 1865 784 250

Web www.prosonix.co.uk